Traws Pharma Inc. (NASDAQ: TRAW) on Wednesday shared interim data from an ongoing randomized, open-label Phase 2 with ratutrelvir, an investigational oral, ritonavir-free Mpro/3CL protease inhibitor.
INNSBRUCK, Austria, Dec. 9, 2025 /PRNewswire/ -- As cyberattacks continue to challenge even the most resilient organisations, the need for clear, trustworthy, and openly documented security testing ...
US sales flat, store visits fell Margins hit by rising coffee prices, tariffs, investment costs China sales rise 2%, facing competition from local chains Oct 29 (Reuters) - Starbucks (SBUX.O), opens ...
OpenAI is building new features within ChatGPT that would make it a direct competitor with workplace productivity suites like Google Workplace and Microsoft Office 365, The Information reported ...
Congressional Republicans approved President Donald Trump’s sweeping tax and spending cuts package, otherwise known as the “big, beautiful bill.” The House GOP ultimately passed the Senate’s ...
Pew Research Center conducted this study to continue tracking news consumption and trust across a wide range of specific news sources. We last published similar reports in 2020 (based on a 2019 survey ...
Azithromycin was effective for the treatment for women with Ureaplasma urealyticum, showing a similar therapeutic effect to that of doxycycline. Results of a systematic review and meta-analysis ...
GameSpot may get a commission from retail offers. While you may be limited to which version of Minecraft you can play based on the device you're using, there are some important differences between ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback